Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Green

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 9, 2010
Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug developmentDiane R Mould, Bruce Green
Journal of Pharmacokinetics and Pharmacodynamics|August 29, 2003
Prospective evaluation of a D-optimal designed population pharmacokinetic studyBruce Green, Stephen B Duffull
British Journal of Clinical Pharmacology|July 10, 2003
Development of a dosing strategy for enoxaparin in obese patientsBruce Green, Stephen B Duffull
British Journal of Clinical Pharmacology|July 17, 2004
What is the best size descriptor to use for pharmacokinetic studies in the obese?Bruce Green, Stephen B Duffull
Expert Opinion on Drug Metabolism & Toxicology|March 23, 2011
The effects of obesity on drug pharmacokinetics in humansGlynn A Morrish, Manjunath P Pai, Bruce Green
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 14, 2017
A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scoresJulia Korell, Bruce Green, John DeVincenzo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 28, 2009
Informative study designs to identify true parameter-covariate relationshipsPhey Yen Han, Carl M J Kirkpatrick, Bruce Green
British Journal of Clinical Pharmacology|June 25, 2010
Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international surveyMichael A Barras, Carl M J Kirkpatrick, Bruce Green
European Journal of Clinical Pharmacology|February 3, 2018
Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapineJulia Korell, Bruce Green, Allan Rae, et al.
Pharmaceutical Research|January 17, 2012
Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant womenJ G Coen van Hasselt, Bruce Green, Glynn A Morrish
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 9, 2010
Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug developmentDiane R Mould, Bruce Green
Journal of Pharmacokinetics and Pharmacodynamics|August 29, 2003
Prospective evaluation of a D-optimal designed population pharmacokinetic studyBruce Green, Stephen B Duffull
British Journal of Clinical Pharmacology|July 10, 2003
Development of a dosing strategy for enoxaparin in obese patientsBruce Green, Stephen B Duffull
British Journal of Clinical Pharmacology|July 17, 2004
What is the best size descriptor to use for pharmacokinetic studies in the obese?Bruce Green, Stephen B Duffull
Expert Opinion on Drug Metabolism & Toxicology|March 23, 2011
The effects of obesity on drug pharmacokinetics in humansGlynn A Morrish, Manjunath P Pai, Bruce Green
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 14, 2017
A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scoresJulia Korell, Bruce Green, John DeVincenzo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 28, 2009
Informative study designs to identify true parameter-covariate relationshipsPhey Yen Han, Carl M J Kirkpatrick, Bruce Green
British Journal of Clinical Pharmacology|June 25, 2010
Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international surveyMichael A Barras, Carl M J Kirkpatrick, Bruce Green
European Journal of Clinical Pharmacology|February 3, 2018
Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapineJulia Korell, Bruce Green, Allan Rae, et al.
Pharmaceutical Research|January 17, 2012
Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant womenJ G Coen van Hasselt, Bruce Green, Glynn A Morrish
Pageof 4